OverviewSuggest Edit
Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.
| Type | Public | |
| Founded | 1991 | |
| HQ | Salt Lake City, US | Map |
| Website | myriad.com | |
| Employee Ratings | More |
Recent NewsAll News
- Liquid Biopsy Market Growth Rate of 23.80% by 2026 Global Industry Size, Share, Trends, COVID-19 Analysis and Technology Advancements by QIAGEN, MDxHealth, CareDx, Inc., Immucor, Inc., Menarini Silicon Biosystems, Guardant Health, Myriad Genetics
- Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference
- Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
- MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action
Key People/Management at Myriad Genetics
Bryan Riggsbee
Interim President and CEO, Chief Financial Officer
Patrick Burke
Executive Vice President, Emerging Products
Raymond Francot
Executive Vice President, International Operations
Bryan Dechairo
Officer, Executive Vice President, Development
Clivetty Martinez
Chief Compliance Officer
Nicole Lambert
Group President, Myriad Oncology, Myriad Women’s Health and Myriad International
Myriad Genetics Office Locations
Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations
Salt Lake City, US (HQ)
320 Wakara Way
Austin, US
3300 Duval Rd
South San Francisco, US
180 Kimball Way
South San Francisco, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
13 Rue Camille Desmoulins
Martinsried, DE
Bunsenstrasse 7
Myriad Genetics Financials and Metrics
Myriad Genetics Revenue
Myriad Genetics's revenue was reported to be $638.60 m in FY, 2020
| USD | |
|---|---|
Revenue (FY, 2020) | 638.6m |
Net income (FY, 2020) | (199.6m) |
EBIT (FY, 2020) | (231.7m) |
Market capitalization (23-Sept-2020) | 900.2m |
Closing stock price (23-Sept-2020) | 12.1 |
Cash (30-Jun-2020) | 163.7m |
EV | 1.0b |
Myriad Genetics's current market capitalization is $900.2 m.
Annual
Quarterly
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 87.9m | 88.7m | 97.4m | 93.3m | 90.6m | 84.9m | 89.9m | 81.2m | |
Accounts Receivable | 113.2m | 121.1m | 123.7m | 119.1m | 116.6m | 142.6m | 4.8m | 118.3m | 102.5m |
Prepaid Expenses | 9.5m | 9.8m | 10.1m | 11.5m | 12.5m | 11.3m | 14.0m | 16.2m | |
Inventories | 38.9m | 38.2m | 33.4m | 35.9m | 33.3m | 31.9m | 28.1m | 28.1m | 30.8m |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 81.1m | 113.2m | 124.6m | (700.0k) | 1.9m | 8.8m | (20.6m) | (28.9m) | (144.1m) |
Depreciation and Amortization | 13.2m | 26.3m | 39.3m | 18.3m | 36.3m | 54.6m | 18.2m | 36.4m | 54.3m |
Inventories | 3.3m | 4.1m | 8.9m | 3.5m | 6.1m | 7.4m | 3.1m | 2.6m | |
Accounts Payable | 400.0k | 3.0m | (2.0m) | (8.4m) | (300.0k) | (8.1m) | (9.3m) | (11.3m) | (2.1m) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 321.4k |
Debt/Equity | 0.3 x |
Debt/Assets | 0.2 x |
Financial Leverage | 1.6 x |
Myriad Genetics Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Myriad Women’s Health | May 29, 2018 | $408.60 m |
| Myriad Neuroscience | August 03, 2016 | $351.60 m |
| Sividon Diagnostics | May 31, 2016 | $56 m |
| Privatklinik Dr. Robert Schindlbeck | February 27, 2015 | $20.10 m |
| Crescendo Bioscience | February 04, 2014 | $270 m |
| Rules-Based Medicine | April 27, 2011 | $80 m |
| Javelin Pharmaceuticals | December 18, 2009 | $95 m |
| NaturNorth Technologies | April 10, 2008 | |
| AssureRx Canada, Ltd | ||
| Assurex Health, Inc. |
Myriad Genetics Cybersecurity Score
Myriad Genetics Revenue Breakdown
Myriad Genetics revenue breakdown by business segment: 7.2% from Pharmaceutical and Clinical Services and 92.8% from Molecular Diagnostic Testing
Myriad Genetics Online and Social Media Presence
6.03k Twitter followers
Myriad Genetics has 6.03k Twitter Followers. The number of followers has increased 0.8% month over month and increased 2% quarter over quarter
Myriad Genetics's Trends
Twitter Engagement Stats for @myriadgenetics
17.1k
Tweets
838
Following
6k
Followers
33
Tweets last 30 days
1.4
Avg. likes per Tweet
93.9%
Tweets with engagement
Myriad Genetics News and Updates
September 14, 2020
Liquid Biopsy Market Growth Rate of 23.80% by 2026 Global Industry Size, Share, Trends, COVID-19 Analysis and Technology Advancements by QIAGEN, MDxHealth, CareDx, Inc., Immucor, Inc., Menarini Silicon Biosystems, Guardant Health, Myriad Genetics
SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Data Bridge Market Research has added a new report titled Global Liquid Biopsy Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. Global Liqu…
February 12, 2020
Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference
SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:30 a.m. EST on Feb…
February 06, 2020
Myriad Genetics Reports Fiscal Second-Quarter 2020 Financial Results
SALT LAKE CITY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced financial results for its fiscal second-quarter 2020, provided an update on recent business highlights…
November 26, 2019
MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action
NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc. from September 2, 2016 through August 13, 2019, inclusive (the "Class Period") of the important November 26, 2019 lead plaintiff...
November 21, 2019
Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients
SALT LAKE CITY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) to help phy…
November 19, 2019
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - MYGN
NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN) and certain of its officers. The class action, filed in United States District Court, for the District of...
Myriad Genetics Blogs
January 02, 2020
When Gray Days Lead to “the Blues”
Fall slump. The winter blahs. Is it almost spring? Weather can have an impact on our daily mood and feelings. For
The post When Gray Days Lead to “the Blues” appeared first on Myriad Genetics, Inc..
October 01, 2019
3 Tips to Help You Prevent Breast Cancer
The post 3 Tips to Help You Prevent Breast Cancer appeared first on Myriad Genetics, Inc..
September 18, 2019
The Importance of Hereditary Cancer Testing for Patients with Pancreatic Cancer
Pancreatic cancer is the third leading cause of death due to cancer.1 Approximately 56,500 people, or 1 in 64, will be diagnosed
The post The Importance of Hereditary Cancer Testing for Patients with Pancreatic Cancer appeared first on Myriad Genetics, Inc..
Myriad Genetics Frequently Asked Questions
When was Myriad Genetics founded?
Myriad Genetics was founded in 1991.
Who are Myriad Genetics key executives?
Myriad Genetics's key executives are Bryan Riggsbee, Patrick Burke and Raymond Francot.
How many employees does Myriad Genetics have?
Myriad Genetics has 2,600 employees.
What is Myriad Genetics revenue?
Latest Myriad Genetics annual revenue is $638.6 m.
What is Myriad Genetics revenue per employee?
Latest Myriad Genetics revenue per employee is $245.6 k.
Who are Myriad Genetics competitors?
Competitors of Myriad Genetics include Progenity, Foundation Medicine and Genomic Health.
Where is Myriad Genetics headquarters?
Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.
Where are Myriad Genetics offices?
Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations.
How many offices does Myriad Genetics have?
Myriad Genetics has 13 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies